| Literature DB >> 31700512 |
Tomoko Tomioka1, Ryokichi Takahashi1, Yosuke Ikumi1, Shuhei Tanaka1, Yoshitaka Ito1, Hiroki Shioiri1, Jiro Koyama1, Kanichi Inoue1.
Abstract
BACKGROUND: Cognitive impairment (CI) increases cardiac mortality among very elderly patients. Percutaneous coronary intervention (PCI) for ischemic heart disease (IHD) patients is considered a favorable strategy for decreasing cardiac mortality. Here, we investigated the influence of CI on cardiac mortality after PCI in very elderly patients.Entities:
Keywords: Cognitive impairments; Family background; Mortality; Octogenarians; Percutaneous coronary intervention
Year: 2019 PMID: 31700512 PMCID: PMC6828605 DOI: 10.11909/j.issn.1671-5411.2019.10.005
Source DB: PubMed Journal: J Geriatr Cardiol ISSN: 1671-5411 Impact factor: 3.327
Comparison of clinical outcomes between the CI group and non-CI group for three years after PCI with univariate analyses.
| Variables | CI ( | Non-CI ( | OR (95% CI) | |
| All-cause mortality | 17 (18%) | 13 (14%) | NS | NS |
| Cardiac mortality | ||||
| Within the 1st year | 12 (29%) | 5 (9%) | 4.1 (1.29–12.67) | < 0.05 |
| Within the 2nd year | 12 (29%) | 6 (11%) | 3.7 (1.27–10.87) | < 0.05 |
| Within the 3rd year | 15 (36%) | 7 (13%) | 4.3 (1.56–11.82) | < 0.05 |
| Adverse cardiac events | 16 (39%) | 9 (17%) | 3.2 (1.23–8.29) | < 0.05 |
CI: cognitive impairment; NS: no significance; OR: odds ratio; PCI: percutaneous coronary intervention.
Clinical characteristics of all patients with or without CI.
| Variables | CI ( | Non-CI ( | |
| Mean follow-up period, days | 775 ± 495 | 1493 ± 785 | < 0.05 |
| Age, yrs | 85.2 ± 3.4 | 84.3 ± 3.1 | NS |
| Male sex | 23 (52%) | 32 (57%) | NS |
| BMI, kg/m2 | 23.2 ± 4.0 | 22.4 ± 3.6 | NS |
| Emergent PCI | 20 (45%) | 21 (37%) | NS |
| Prevalence of CHF on admission | 20 (45%) | 16 (29%) | NS |
| Comorbidity | |||
| Cardiac disease | 11 (39%) | 7 (18%) | NS |
| AF | 6 (15%) | 4 (7%) | NS |
| Conduction disturbance | 0 (0%) | 3 (6%) | NS |
| IHD | 0 (0%) | 2 (4%) | NS |
| Chronic heart failure | 6 (15%) | 2 (4%) | NS |
| Cerebrovascular disease | 5 (11%) | 4 (4%) | NS |
| Respiratory disease | 2 (4%) | 5 (9%) | NS |
| Malignant disease | 1 (2%) | 1 (2%) | NS |
| Major bleeding | 2 (4%) | 4 (4%) | NS |
| Hypertension | 33 (75%) | 44 (78%) | NS |
| Diabetes | 14 (32%) | 19 (36%) | NS |
| Chronic kidney disease | 23 (57%) | 24 (44%) | |
| Prevalence of physical disability on admission | 20 (50%) | 13 (24%) | < 0.05 |
| Dyslipidemia | 22 (50%) | 42 (75%) | < 0.05 |
| Laboratory data | |||
| Hemoglobin, g/dL | 12.3 ± 1.82 | 12.5 ± 1.69 | NS |
| Lymphocyte subset, % | 21.1 ± 11.1 | 23.5 ± 8.0 | NS |
| Albumin, g/mL | 3.76 ± 0.44 | 3.84 ± 0.53 | NS |
| eGFR, mL/min·1.73 m2 | 56 ± 18.4 | 61.3 ± 21.6 | NS |
| BNP on admission, pg/mL | 402 ± 528 | 277 ± 544 | NS |
| BNP on chronic phase, pg/mL | 426 ± 870 | 105 ± 115 | < 0.05 |
| Serum Na, mEq/L | 140 ± 4.56 | 139 ± 4.23 | NS |
| Cardiac function on admission | |||
| LVEF, % | 55 ± 1.9 | 61 ± 10.7 | < 0.05 |
| LAD, mm | 43 ± 8.4 | 42 ± 6.4 | NS |
| E/A | 0.89 ± 0.52 | 0.71 ± 0.24 | NS |
| LVH (IVS + PW > 21 mm) | 8 (18%) | 8 (14%) | NS |
| Cardiac function at the chronic phase | |||
| LVEF, % | 56 ± 12.9 | 63 ± 9.7 | < 0.05 |
| LAD, mm | 44.3 ± 7.07 | 41 ± 6.8 | NS |
| E/A | 0.69 ± 0.24 | 0.72 ± 0.29 | NS |
| LVH (IVS + PW > 21 mm) | 8 (18%) | 8 (14%) | NS |
| Medication | |||
| Antiplatelet | 42 (95%) | 54 (98%) | NS |
| ACE/ARB | 29 (66%) | 40 (71%) | NS |
| Diuretics | 15 (34%) | 15 (26%) | NS |
| Beta blocker | 24 (54%) | 28 (50%) | NS |
| Anti-aldosterone agent | 10 (22%) | 8 (14%) | NS |
| Statin | 28 (52%) | 42 (75%) | NS |
Data are presented as means ± SD or n (%). ACE: angiotensin-converting enzyme; AF: atrial fibrillation; ARB: angiotensin II receptor blocker; BMI: body mass index; BNP: brain natriuretic peptide; CHF: congestive heart failure; CI: cognitive impairment; eGFR: estimated glomerular filtration rate; IHD: ischemic heart disease; IVS: interventricular septum; LAD: left atrial dimension; LVEF: left ventricular ejection fraction; LVH: left ventricular hypertrophy; NS: no significance; PCI: percutaneous coronary intervention; PW: posterior wall.
Figure 1.Cardiac mortality after PCI in patients with and without CI.
Kaplan-Meier curve comparing cardiac mortality after PCI between CI and non-CI patients in the 3-year follow-up period. CI: cognitive impairment; PCI: percutaneous coronary intervention.
Factors influencing cardiac death in all following periods after PCI with multivariate logistic analyses.
| Variables | OR (95% CI) | |
| Prevalence of CI | 3.8 (1.19–12.32) | 0.02 |
| Age | 1.2 (1.19–12.32) | 0.04 |
| eGFR on admission | 1.0 (0.97–1.03) | 0.86 |
| Comorbid with cardiac disease | 2.3 (0.55–9.48) | 0.24 |
| Physical disability on admission | 1.1 (0.30–3.97) | 0.88 |
| Prevalence of CHF on admission | 2.9 (0.92–9.35) | 0.06 |
CHF: congestive heart failure; CI: cognitive impairment; eGFR: estimated glomerular filtration rate; OR: odds ratio; PCI: percutaneous coronary intervention.
Factors influencing cardiac death after PCI in all following periods in the CI group with multivariate logistic analyses.
| Variables | OR (95% CI) | |
| Living with CI partner | 30.7 (1.24–763) | 0.03 |
| Age | 1.4 (0.98–2.22) | 0.06 |
| BNP on admission | 1.0 (0.99–1.00) | 0.73 |
| Comorbid with cardiac disease | 9.9 (1.27–77.35) | 0.02 |
| Physical disability on admission | 2.0 (0.32–12.81) | 0.45 |
BNP: brain natriuretic peptide; CI: cognitive impairment; OR: odds ratio; PCI: percutaneous coronary intervention.